SuperworthBlack Hawk Acquisition EPS BKHA
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Aug 31, 2026
- n/m
- a quarter missing
- Latest quarter, Q3 FY26
- $0.26
- +767% on a year earlier
Black Hawk Acquisition's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q3 FY26, it was $0.26, up 767% on the same quarter a year before.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q3 FY26 | $0.26 | +767% | |
| Q2 FY26 | $0.02 | −67% | |
| Q1 FY26 | $0.03 | −57% | |
| Q3 FY25 | $0.03 | n/a | |
| Q2 FY25 | $0.06 | n/a | |
| Q1 FY25 | $0.07 | n/a |
Against its peers
Companies in Healthcare nearest Black Hawk Acquisition's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BKHABlack Hawk Acquisition | n/m | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Black Hawk Acquisition
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.